NYSE:TARO Taro Pharmaceutical Industries (TARO) Stock Forecast, Price & News $38.04 -0.14 (-0.37%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$37.93▼$38.8350-Day Range$23.00▼$38.1252-Week Range$22.89▼$40.15Volume42,315 shsAverage Volume20,186 shsMarket Capitalization$1.43 billionP/E Ratio56.78Dividend YieldN/APrice Target$35.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Taro Pharmaceutical Industries MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8.0% Downside$35.00 Price TargetShort InterestHealthy0.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector872nd out of 983 stocksPharmaceutical Preparations Industry438th out of 486 stocks 1.5 Analyst's Opinion Consensus RatingTaro Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Taro Pharmaceutical Industries has a forecasted downside of 8.0% from its current price of $38.04.Amount of Analyst CoverageTaro Pharmaceutical Industries has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.86% of the float of Taro Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTaro Pharmaceutical Industries has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Taro Pharmaceutical Industries has recently increased by 24.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaro Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTaro Pharmaceutical Industries does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARO. Previous Next 1.8 News and Social Media Coverage News SentimentTaro Pharmaceutical Industries has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Taro Pharmaceutical Industries this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TARO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Taro Pharmaceutical Industries is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.45% of the stock of Taro Pharmaceutical Industries is held by institutions. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Taro Pharmaceutical Industries is 56.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Taro Pharmaceutical Industries is 56.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.67.Price to Book Value per Share RatioTaro Pharmaceutical Industries has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Taro Pharmaceutical Industries (NYSE:TARO) StockTaro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.Read More Receive TARO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TARO Stock News HeadlinesJune 2, 2023 | seekingalpha.comTaro Pharmaceutical: Potential Value In Sun Pharma OfferJune 2, 2023 | msn.comSun Pharma's Latest Cash Offer for Taro Might Actually Seal the Deal This Time AroundJune 3, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 1, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Sees Unusually-High Trading VolumeMay 30, 2023 | finance.yahoo.comWhy Shares of Taro Pharmaceutical Are Rising TuesdayMay 30, 2023 | msn.comHeartBeam, Taro top healthcare gainers; Enveric, Bright Health among losersMay 30, 2023 | marketwatch.comTaro Pharmaceutical Shares Surge Premarket as Sun Pharma Proposes Buyout >TAROMay 30, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Stock Rating Upgraded by StockNews.comJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 27, 2023 | seekingalpha.comTaro Pharma weighing offer from Sun Pharma to acquire company at $38 shareMay 24, 2023 | msn.comTaro Pharmaceutical misses top an bottom line consensus for Q1May 23, 2023 | finance.yahoo.comTaro Provides Results for Year Ended March 31, 2023May 23, 2023 | markets.businessinsider.comWhat Wall Street expects from Taro Pharmaceutical Industries's earningsMay 22, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Downgraded by StockNews.comMay 22, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (TARO) to Release Earnings on TuesdayMay 16, 2023 | marketwatch.com2023 to 2030, Hydrocortisone Butyrate Market: Business Strategic and Growth AnalysisMay 15, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Raised to "Buy" at StockNews.comMay 12, 2023 | marketwatch.comNystatin and Triamcinolone Acetonide Market 2023 to Hit Statistical Significance Value by 2030May 11, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Shares Gap Up to $27.37May 10, 2023 | marketwatch.comFuture of Clindamycin Phosphate Topical Market 2023: Active Key Players and Emerging Trends in Industry till 2030May 10, 2023 | marketwatch.comLice Treatment Market Qualitative and Quantitative Inputs Drive Industry GrowthMay 8, 2023 | marketwatch.comThe Takotsubo Syndrome Therapeutics Market Trends: 2023 Segmentation in Customer TargetingMay 4, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Downgraded by StockNews.com to HoldMay 3, 2023 | marketwatch.comEnalapril Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2031April 28, 2023 | marketwatch.comUrticaria Drug Market Business Report [2023-2030]April 27, 2023 | marketwatch.comOxcarbazepine Market Market Trends By 2030April 27, 2023 | americanbankingnews.comStockNews.com Upgrades Taro Pharmaceutical Industries (NYSE:TARO) to BuySee More Headlines TARO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARO Company Calendar Last Earnings10/28/2021Today6/03/2023Next Earnings (Estimated)7/26/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TARO CUSIPN/A CIK906338 Webwww.taro.com Phone(724) 847-5700Fax914-345-6169Employees1,455Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside-8.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.67 Trailing P/E Ratio56.78 Forward P/E RatioN/A P/E GrowthN/ANet Income$25.44 million Net Margins4.44% Pretax Margin6.67% Return on Equity1.48% Return on Assets1.20% Debt Debt-to-Equity RatioN/A Current Ratio3.47 Quick Ratio2.88 Sales & Book Value Annual Sales$572.95 million Price / Sales2.50 Cash Flow$1.80 per share Price / Cash Flow21.10 Book Value$46.05 per share Price / Book0.83Miscellaneous Outstanding Shares37,585,000Free Float32,398,000Market Cap$1.43 billion OptionableOptionable Beta0.60 Key ExecutivesUday Vijaykumar BaldotaChief Executive Officer & DirectorWilliam J. CooteChief Financial, VP & Accounting OfficerHagai ReingoldVice President & Head-OperationsItamar KarsentiVice President & Head-OperationsAvi AvramoffVice President & Head-Research & DevelopmentKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXAgios PharmaceuticalsNASDAQ:AGIOGemini TherapeuticsNASDAQ:GMTXAurinia PharmaceuticalsNASDAQ:AUPHDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Sold 72,070 shares on 5/22/2023Ownership: 0.551%Hotchkis & Wiley Capital Management LLCBought 4,700 shares on 5/16/2023Ownership: 0.756%State Street CorpBought 1,000 shares on 5/16/2023Ownership: 0.154%Balyasny Asset Management L.P.Bought 14,056 shares on 5/16/2023Ownership: 0.037%BlueCrest Capital Management LtdBought 9,192 shares on 5/16/2023Ownership: 0.024%View All Institutional Transactions TARO Stock - Frequently Asked Questions Should I buy or sell Taro Pharmaceutical Industries stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TARO shares. View TARO analyst ratings or view top-rated stocks. What is Taro Pharmaceutical Industries' stock price forecast for 2023? 1 Wall Street research analysts have issued 12-month price targets for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 8.0%. View analysts price targets for TARO or view top-rated stocks among Wall Street analysts. How have TARO shares performed in 2023? Taro Pharmaceutical Industries' stock was trading at $29.04 at the start of the year. Since then, TARO shares have increased by 31.0% and is now trading at $38.04. View the best growth stocks for 2023 here. Are investors shorting Taro Pharmaceutical Industries? Taro Pharmaceutical Industries saw a increase in short interest in May. As of May 15th, there was short interest totaling 69,200 shares, an increase of 24.2% from the April 30th total of 55,700 shares. Based on an average trading volume of 20,300 shares, the days-to-cover ratio is presently 3.4 days. Currently, 0.9% of the company's stock are sold short. View Taro Pharmaceutical Industries' Short Interest. When is Taro Pharmaceutical Industries' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. View our TARO earnings forecast. How were Taro Pharmaceutical Industries' earnings last quarter? Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings data on Thursday, October, 28th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.02 by $0.36. The business earned $131.99 million during the quarter, compared to analysts' expectations of $153.23 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 1.48% and a net margin of 4.44%. During the same period last year, the company earned $1.18 EPS. What ETFs hold Taro Pharmaceutical Industries' stock? ETFs with the largest weight of Taro Pharmaceutical Industries (NYSE:TARO) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) and iShares MSCI Israel ETF (EIS).VanEck Israel ETF (ISRA). What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO? 11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Taro Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV). What is Taro Pharmaceutical Industries' stock symbol? Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO." Who are Taro Pharmaceutical Industries' major shareholders? Taro Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (1.71%), Renaissance Technologies LLC (1.59%), Dimensional Fund Advisors LP (1.52%), Brandes Investment Partners LP (1.23%), Hotchkis & Wiley Capital Management LLC (0.76%) and Acadian Asset Management LLC (0.69%). How do I buy shares of Taro Pharmaceutical Industries? Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Taro Pharmaceutical Industries' stock price today? One share of TARO stock can currently be purchased for approximately $38.04. How much money does Taro Pharmaceutical Industries make? Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.43 billion and generates $572.95 million in revenue each year. The company earns $25.44 million in net income (profit) each year or $0.67 on an earnings per share basis. How many employees does Taro Pharmaceutical Industries have? The company employs 1,455 workers across the globe. How can I contact Taro Pharmaceutical Industries? Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169. This page (NYSE:TARO) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taro Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.